Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Hoffmann-La Roche
Azienda Ospedaliero-Universitaria di Parma
St. Jude Children's Research Hospital
Abramson Cancer Center at Penn Medicine
Adela, Inc
Mayo Clinic
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
AVM Biotechnology Inc
Washington University School of Medicine
Trishula Therapeutics, Inc.
Tempus AI
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
University Health Network, Toronto
Massachusetts General Hospital
University Medicine Greifswald
Cyteir Therapeutics, Inc.
Taproot Health
Vector Vitale LLC
Zhejiang Provincial People's Hospital
Cedars-Sinai Medical Center
Sanguine Biosciences
Celldex Therapeutics
OHSU Knight Cancer Institute
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Hoffmann-La Roche
Biologics & Biosimilars Collective Intelligence Consortium
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Hospital Universitario San Ignacio
Weprom
Hospices Civils de Lyon
AstraZeneca
M.D. Anderson Cancer Center
First Affiliated Hospital of Wenzhou Medical University
National Cancer Institute (NCI)
Tocagen Inc.
Shenzhen BinDeBio Ltd.
Tel-Aviv Sourasky Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
sigma-tau i.f.r. S.p.A.
Incyte Corporation